The US Food and Drug Administration (FDA) has allowed marketing of the Xlumena, Inc's Axios Stent and Delivery System for treating pseudocysts (fluid and tissue filled cavities) that form in the ...

MOUNTAIN VIEW, Calif., July 17, 2012 /PRNewswire/ -- Xlumena, Inc. announces that it has received CE Mark approval to market its AXIOS Stent and Delivery System for biliary tract drainage. The device ...

Boston Scientific Corporation announced today the commercial launch of the AXIOS Stent and Electrocautery Enhanced Delivery System. It is designed to help physicians manage serious complications from ...

MOUNTAIN VIEW, Calif., May 15, 2012 /PRNewswire/ -- Xlumena, Inc. announces the publication of a scientific paper describing the first human study of the AXIOS™ Stent and Delivery System. The article, ...

The first stent specifically designed to treat pancreatic pseudocysts yesterday was cleared for marketing by the US Food and Drug Administration (FDA). The Axios stent and delivery system from Xlumena ...

In a bid to extend its footprint in the multibillion-dollar endoscopy equipment market, Boston Scientific Corporation BSX has commercially launched its FDA-cleared Axios stent and electrocautery ...

Xlumena, Inc., a leader in the development of advanced endoscopic devices, today announced the close of a $25 million Series C financing. Led by Third Point LLC, the round of funding includes existing ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced it will allow marketing of the Axios Stent and Delivery System to treat fluid- and ...

On March 22, 2016, Boston Scientific announced the launch of the AXIOS Stent and Electrocautery Enhanced Delivery System. According to its website, the stent and delivery system helps physicians treat ...

Axios Stent and Electrocautery Enhanced Delivery System--Courtesy of Boston Scientific Boston Scientific ($BSX) launched the Axios Stent and Electrocautery Enhanced ...